ImmunityBio Q1 net product revenue $44.2M, up 168% YoY; ANKTIVA approvals expand; cash $381M

ImmunityBio, Inc.

2026-Q1 EPS reported -$0.62 revenue$44,206,000

Q1 2026 net product revenue $44.2M, up 168% YoY ($16.5M) and 15% sequentially from Q4 2025 ($38.3M).
ANKTIVA unit sales up 168% YoY; approved in 5 jurisdictions covering ~34 countries, including first Asia approval in Macau.
Cash and marketable securities $380.9M as of March 31, 2026, up from $242.8M at Dec 31, 2025.
Pivotal BCG-naïve CIS trial fully enrolled; sBLA submission on track for 2026.
GAAP net loss $632.8M driven by non-cash fair value changes; adjusted net loss $86.2M vs $82.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ImmunityBio, Inc. reported the three months ended March 31, 2026 results: revenue $44.2 million.

Period: the three months ended March 31, 2026
Revenue: $44.2 million
Result: reported results

Exact text from the filing

9 – Financial Statements and Exhibits. --- EX-99.1 (EX-99.1) --- ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million • Q1 2026 Revenue Growth with Continued Strong

View on SEC.gov

Browse all earnings releases →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001326110-26-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.